Theresa E. Leon

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.

Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.

Journal: Blood advances

Published: November 19, 2024

Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.

Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.

Journal: Blood advances

Published: November 19, 2024

Endogenous LXR signaling controls pulmonary surfactant homeostasis and prevents lung inflammation.

Endogenous LXR signaling controls pulmonary surfactant homeostasis and prevents lung inflammation.

Journal: Cellular and molecular life sciences : CMLS

Published: February 23, 2024

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.

Journal: Blood

Published: August 17, 2021

Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment.

Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment.

Journal: Cancer research

Published: October 26, 2019

EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress.

EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress.

Journal: Cancer discovery

Published: August 23, 2019

Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial.

Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial.

Journal: Haematologica

Published: March 10, 2018

JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.

JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.

Journal: The Journal of experimental medicine

Published: March 15, 2017

APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.

APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.

Journal: Leukemia

Published: November 14, 2016

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.

Journal: Blood

Published: September 27, 2016

The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism.

The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism.

Journal: Cell reports

Published: January 29, 2016

The nuclear receptor LXR modulates interleukin-18 levels in macrophages through multiple mechanisms.

The nuclear receptor LXR modulates interleukin-18 levels in macrophages through multiple mechanisms.

Journal: Scientific reports

Published: November 09, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026